1. Exposure of R6/2 mice in an enriched environment augments P42 therapy efficacy on Huntington's disease progression. (15th March 2021) Authors: Couly, Simon; Carles, Allison; Denus, Morgane; Benigno-Anton, Lorraine; Maschat, Florence; Maurice, Tangui Journal: Neuropharmacology Issue: Volume 186(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Improvement of BDNF signalling by P42 peptide in Huntington's disease. (1st June 2018) Authors: Couly, Simon; Paucard, Alexia; Bonneaud, Nathalie; Maurice, Tangui; Benigno, Lorraine; Jourdan, Christophe; Cohen-Solal, Catherine; Vignes, Michel; Maschat, Florence Journal: Human molecular genetics Issue: Volume 27:Number 17(2018:Sep. 01) Page Start: 3012 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. L21 P42, a 23AA domain of the huntingtin protein: its protective properties and its modes of action. (13th September 2016) Authors: Maschat, Florence; Couly, Simon; Marelli, Cecilia; Vignes, Michel; Paucard, Alexia; Benigno, Lorraine; Maurel, Patrick; Jourdan, Christophe; Bonneaud, Nathalie Journal: Journal of neurology, neurosurgery and psychiatry Issue: Volume 87(2016)Supplement 1 Page Start: A97 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. The P42 peptide and Peptide-based therapies for Huntington's disease. Issue 1 (December 2016) Authors: Marelli, Cecilia; Maschat, Florence Journal: Orphanet journal of rare diseases Issue: Volume 11:Issue 1(2016) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗